O	0	1	A
O	2	13	prospective
O	13	14	,
O	15	26	multicenter
O	26	27	,
O	28	38	controlled
O	38	39	,
O	40	53	observational
O	54	59	study
O	60	62	to
O	63	71	evaluate
O	72	75	the
O	76	84	efficacy
O	85	87	of
O	88	89	a
B-intervention	90	97	patient
I-intervention	98	105	support
I-intervention	106	113	program
O	114	116	in
O	117	126	improving
O	127	135	patients
O	135	136	'
O	137	148	persistence
O	149	151	to
O	152	160	adjuvant
O	161	170	aromatase
O	171	180	inhibitor
O	181	191	medication
O	192	195	for
O	196	210	postmenopausal
O	210	211	,
O	212	217	early
O	218	223	stage
O	224	230	breast
O	231	237	cancer
O	237	238	.

O	239	244	Since
O	245	248	the
O	249	253	rate
O	254	256	of
O	257	268	persistence
O	269	271	to
O	272	280	adjuvant
O	281	290	endocrine
O	291	298	therapy
O	299	303	such
O	304	306	as
O	307	308	5
O	308	309	-
O	309	313	year
O	314	323	aromatase
O	324	334	inhibitors
O	335	336	(
O	336	338	AI
O	338	339	)
O	340	345	would
O	346	354	decrease
O	355	359	over
O	360	364	time
O	365	367	in
O	368	376	patients
O	377	381	with
O	382	389	hormone
O	389	390	-
O	390	399	sensitive
O	400	406	breast
O	407	413	cancer
O	413	414	,
O	415	417	it
O	418	420	is
O	421	430	necessary
O	431	433	to
O	434	445	investigate
O	446	448	if
O	449	450	a
O	451	458	patient
O	459	466	support
O	467	474	program
O	475	480	could
O	481	487	modify
O	488	496	patients
O	496	497	'
O	498	505	beliefs
O	506	509	and
O	510	517	improve
O	518	523	their
O	524	535	persistence
O	536	538	to
O	539	541	AI
O	542	551	treatment
O	551	552	.

O	553	557	This
O	558	561	was
O	562	563	a
O	564	575	prospective
O	575	576	,
O	577	588	multicenter
O	588	589	,
O	590	600	controlled
O	600	601	,
O	602	615	observational
O	616	621	study
O	622	624	to
O	625	633	evaluate
O	634	637	the
O	638	646	efficacy
O	647	649	of
O	650	651	a
O	652	659	patient
O	660	667	support
O	668	675	program
O	676	678	in
O	679	688	improving
O	689	703	postmenopausal
O	704	712	patients
O	712	713	'
O	714	725	persistence
O	726	728	to
O	729	737	adjuvant
O	738	740	AI
O	741	751	medication
O	752	755	for
O	756	761	early
O	762	767	stage
O	768	774	breast
O	775	781	cancer
O	782	783	(
O	783	794	NCT00769080
O	794	795	)
O	795	796	.

O	797	800	The
O	801	808	primary
O	809	818	objective
O	819	822	was
O	823	825	to
O	826	833	compare
O	834	837	the
B-outcome-Measure	838	843	rates
I-outcome-Measure	844	846	of
I-outcome-Measure	847	848	1
I-outcome-Measure	848	849	-
I-outcome-Measure	849	853	year
I-outcome-Measure	854	865	persistence
O	866	868	to
O	869	876	upfront
O	877	885	adjuvant
O	886	888	AI
O	889	892	for
O	893	901	patients
O	902	904	in
O	905	908	the
O	909	912	two
O	913	926	observational
O	927	931	arms
O	932	933	(
B-control	933	941	standard
I-control	942	951	treatment
I-control	952	957	group
O	958	961	and
O	962	970	standard
O	971	980	treatment
O	981	985	plus
O	986	993	patient
O	994	1001	support
O	1002	1009	program
O	1010	1015	group
O	1015	1016	)
O	1016	1017	.

O	1018	1020	In
O	1021	1025	this
O	1026	1031	study
O	1031	1032	,
B-control-participants	1033	1036	262
O	1037	1045	patients
O	1046	1050	were
O	1051	1059	enrolled
O	1060	1062	in
O	1063	1066	the
O	1067	1075	standard
O	1076	1085	treatment
O	1086	1091	group
O	1092	1095	and
B-intervention-participants	1096	1099	241
O	1100	1108	patients
O	1109	1111	in
O	1112	1115	the
O	1116	1124	standard
O	1125	1134	treatment
O	1135	1139	plus
O	1140	1147	patient
O	1148	1155	support
O	1156	1163	program
O	1164	1169	group
O	1169	1170	.

O	1171	1174	The
B-outcome	1175	1179	mean
I-outcome	1180	1181	1
I-outcome	1181	1182	-
I-outcome	1182	1186	year
I-outcome	1187	1198	persistence
I-outcome	1199	1204	rates
O	1205	1209	were
B-cv-cont-mean	1210	1212	95
I-cv-cont-mean	1212	1213	.
I-cv-cont-mean	1213	1214	9
O	1215	1218	and
B-iv-cont-mean	1219	1221	95
I-iv-cont-mean	1221	1222	.
I-iv-cont-mean	1222	1223	8
I-iv-cont-mean	1223	1224	%
O	1225	1228	for
O	1229	1232	the
O	1233	1241	standard
O	1242	1251	treatment
O	1252	1257	group
O	1258	1261	and
O	1262	1265	the
O	1266	1274	standard
O	1275	1284	treatment
O	1285	1289	plus
O	1290	1297	patient
O	1298	1305	support
O	1306	1313	program
O	1314	1319	group
O	1319	1320	,
O	1321	1333	respectively
O	1334	1335	(
O	1335	1336	P
O	1336	1337	=
O	1337	1338	0
O	1338	1339	.
O	1339	1341	95
O	1341	1342	)
O	1342	1343	.

O	1344	1347	The
B-outcome	1348	1352	mean
I-outcome	1353	1358	times
I-outcome	1359	1361	to
I-outcome	1362	1371	treatment
I-outcome	1372	1387	discontinuation
O	1388	1392	were
B-cv-cont-mean	1393	1396	231
I-cv-cont-mean	1396	1397	.
I-cv-cont-mean	1397	1398	2
I-cv-cont-mean	1399	1403	days
O	1404	1406	in
O	1407	1410	the
O	1411	1419	standard
O	1420	1429	treatment
O	1430	1435	group
O	1436	1439	and
B-iv-cont-mean	1440	1443	227
I-iv-cont-mean	1443	1444	.
I-iv-cont-mean	1444	1445	8
I-iv-cont-mean	1446	1450	days
O	1451	1453	in
O	1454	1457	the
O	1458	1466	standard
O	1467	1476	treatment
O	1477	1481	plus
O	1482	1489	patient
O	1490	1497	support
O	1498	1505	program
O	1506	1511	group
O	1511	1512	,
O	1513	1517	with
O	1518	1520	no
O	1521	1534	statistically
O	1535	1546	significant
O	1547	1557	difference
O	1558	1565	between
O	1566	1569	the
O	1570	1573	two
O	1574	1580	groups
O	1581	1582	(
O	1582	1583	P
O	1583	1584	=
O	1584	1585	0
O	1585	1586	.
O	1586	1588	96
O	1588	1589	)
O	1589	1590	.

O	1591	1596	There
O	1597	1600	was
O	1601	1605	also
O	1606	1608	no
O	1609	1622	statistically
O	1623	1634	significant
O	1635	1645	difference
O	1646	1648	in
O	1649	1652	the
O	1653	1659	reason
O	1660	1663	for
B-outcome	1664	1673	treatment
I-outcome	1674	1689	discontinuation
O	1690	1691	(
O	1691	1692	P
O	1692	1693	=
O	1693	1694	0
O	1694	1695	.
O	1695	1697	32
O	1697	1698	)
O	1698	1699	.

O	1700	1705	There
O	1706	1709	was
O	1710	1711	a
O	1712	1723	significant
O	1724	1736	relationship
O	1737	1744	between
O	1745	1748	the
O	1749	1756	patient
O	1757	1765	centered
O	1766	1770	care
O	1771	1784	questionnaire
O	1785	1788	and
O	1789	1793	poor
O	1794	1805	persistence
O	1806	1807	(
O	1807	1811	odds
O	1812	1817	ratio
O	1817	1818	=
O	1818	1819	3
O	1819	1820	.
O	1820	1821	9
O	1821	1822	;
O	1823	1825	95
O	1825	1826	%
O	1827	1829	CI
O	1829	1830	,
O	1831	1832	1
O	1832	1833	.
O	1833	1834	1
O	1834	1835	-
O	1835	1837	13
O	1837	1838	.
O	1838	1839	7
O	1839	1840	;
O	1841	1842	P
O	1842	1843	=
O	1843	1844	0
O	1844	1845	.
O	1845	1848	035
O	1848	1849	)
O	1849	1850	,
O	1851	1861	suggesting
O	1862	1866	that
O	1867	1870	the
B-outcome	1871	1882	persistence
I-outcome	1883	1887	rate
O	1888	1890	of
O	1891	1899	patients
O	1900	1904	with
O	1905	1909	whom
O	1910	1913	the
O	1914	1920	doctor
O	1921	1927	always
O	1928	1930	or
O	1931	1938	usually
O	1939	1945	spends
O	1946	1950	time
O	1951	1953	is
O	1954	1961	greater
O	1962	1966	than
O	1967	1971	that
O	1972	1974	of
O	1975	1983	patients
O	1984	1988	with
O	1989	1993	whom
O	1994	1997	the
O	1998	2004	doctor
O	2005	2014	sometimes
O	2015	2017	or
O	2018	2023	never
O	2024	2030	spends
O	2031	2035	time
O	2035	2036	.

O	2037	2045	Patients
O	2045	2046	'
O	2047	2058	persistence
O	2059	2061	to
O	2062	2070	adjuvant
O	2071	2073	AI
O	2074	2084	medication
O	2085	2088	for
O	2089	2103	postmenopausal
O	2103	2104	,
O	2105	2110	early
O	2111	2116	stage
O	2117	2123	breast
O	2124	2130	cancer
O	2131	2133	is
O	2134	2144	relatively
O	2145	2149	high
O	2150	2152	in
O	2153	2156	the
O	2157	2162	first
O	2163	2167	year
O	2168	2171	and
O	2172	2174	is
O	2175	2178	not
O	2179	2192	significantly
O	2193	2202	increased
O	2203	2205	by
O	2206	2212	adding
O	2213	2214	a
O	2215	2222	patient
O	2223	2230	support
O	2231	2238	program
O	2239	2241	to
O	2242	2250	standard
O	2251	2260	treatment
O	2260	2261	.
